The Clinical Characteristics and Prognosis of Patients with Acute Myeloid Leukemia Combine Paroxysmal Nocturnal Hemoglobinuria.
10.19746/j.cnki.issn.1009-2137.2021.04.010
- Author:
Jing WEN
1
;
Hao WANG
1
;
Jia XIE
1
;
Guang LI
1
;
Zhen-Zhen LI
1
;
Xiao-Bo ZHANG
1
;
Rui SHI
1
;
Yan-Ping SONG
2
Author Information
1. Department of Hematology， Xi'an Central Hospital Affiliated to Xi'an Jiaotong University，Xi'an 710003, Shaanxi Province, China.
2. Department of Hematology， Xi'an Central Hospital Affiliated to Xi'an Jiaotong University，Xi'an 710003, Shaanxi Province, China,E-mail:xjtusyp@163.com.
- Publication Type:Journal Article
- MeSH:
Hemoglobinuria, Paroxysmal;
Humans;
Induction Chemotherapy;
Leukemia, Myeloid, Acute/drug therapy*;
Prognosis;
Remission Induction;
Retrospective Studies
- From:
Journal of Experimental Hematology
2021;29(4):1080-1084
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical characteristics and prognosis of patients with acute myeloid leukemia(AML) combined with paroxysmal nocturnal hemoglobinuria(PNH).
METHODS:The clinical data of 13 AML combined with PNH patients treated in our hospital from January 2017 to May 2019 were collected and retrospective analyzed. The complete remission(CR) rate for induction chemotherapy was analyzed. The level of PNH
RESULTS:Among the 13 patients, 11 (84.6%) cases were CR after first induction chemotherapy. The median overall survival(OS) time was 17 months(0-30 months), the median progression-free survival(PFS) time was 16 months(2-26 months). There were no significant difference in the number of PNH
CONCLUSION:The patients of AML combined with PNH have higher CR rate after the first induction chemotherapy. The level of WBC and LDH at first diagnosed are the factors that affecting the OS of the patients. The OS of patients with WBC lower than 10×10
